An Evendale-based medical device company scored a major FDA approval on July 9, and is pushing ahead with plans to open a manufacturing center in Springdale and add approximately 257 jobs across Southwest Ohio.
Enable Injections Inc., founded in 2010 by CEO Mike Hooven, received federal approval for its CirCliq injector to deliver Sanofi's cancer drug Sarclisa to patients with multiple myeloma. Hooven called the approval the "most significant milestone to date in its 16-year history."
The company, considered a unicorn valued at more than $1 billion in the Cincinnati startup community, has committed to investing about $124 million in its regional expansion, according to JobsOhio. That includes the new Springdale manufacturing center and an expanded headquarters in Evendale.
What the device does
The CirCliq is a palm-sized, hands-free wearable injector. Patients push a button and the device delivers large volumes of medication through a retractable 30-gauge needle, thinner and shorter than needles commonly used for large-volume injections. Multiple myeloma patients often endure hours-long IV infusions or manual injections; the on-body device is meant to cut that burden.
According to Sanofi, Sarclisa Escena delivered via CirCliq is the first anticancer treatment administered through an on-body injector.
Clinical backing
The FDA based its decision on the phase 3 Iraklia study, which showed a 71.1% objective response rate for Sarclisa Escena via the on-body injector compared with 70.5% for the IV version. Injection-site reactions occurred in about 0.4% of more than 5,000 injections during trials, and most were mild, according to Sanofi's trial data.
Sanofi's $30 million investment
In January 2026, Sanofi made a $30 million strategic investment in Enable to accelerate manufacturing and supply-chain capabilities, according to a company press release. Hooven said at the time that the funding "shows support of the enFuse platform."
No specific opening date for the Springdale manufacturing center has been announced. JobsOhio lists the expansion as committing to 257 new high-paying positions and $124 million in investment across the region.
